Alzheimer Disease Clinical Trial
Official title:
Dementia-specific Intervention of Advance Care Planning
This is a pilot study that aims to create a dementia-specific intervention of advance care
planning (ACP) and test its feasibility and acceptance with min 20 max 30 patient-relative
dyads.
The intervention is adapted from the Multiprofessional advance care planning and shared
decision-making for end of life care (MAPS) Trials 1 and 2 made at the Zurich University
Hospital.
The study design is longitudinal (historic): all the dyads will be asked to go through the
process (4 visits, see 9.3 Procedures at each visit).
Study background and aims:
Advance care planning (ACP) is a structured communication process between an individual, his
family, and his healthcare agent (if existing), facilitated by a healthcare provider. The aim
is to identify the personal values of the individual, reflect on the meanings and
consequences of anticipated illness scenarios, define goals and preferences of care for these
situations, issue appropriate documents and legal instruments that will help direct future
healthcare decisions, and review these steps at adequate intervals. ACP emphasizes
communication in anticipation of a future deterioration of a person's health. Even though
dementia entails the loss of decision-making capacity, advance care planning is yet to become
widespread. This study aims to close the gap and create a dementia-specific ACP intervention
that:
- Support patient autonomy through advance care planning
- Improve participants' satisfaction and perceived control;
- Increase planning decisions and surrogate's knowledge of patients' preferences and
values.
Procedure and measure:
Pre-intervention assessment (Visit 1):
If the patient and her/his relative have both consented to the study, the PI will ask the
patient and her/his relative to fil out psychometric scales: Hospital anxiety and depression
scale (HADS), Decisional conflict scale, Personal autonomy scale and Zarit Burden Inventory.
Then, the PI will realize a semi-structured interview on patient's val-ues and treatment
preferences and caregiver's knowledge of patient's preferences and care planning decisions
that have already been made. Participants will also be asked to hand out a copy of any
pre-existing advance directives or other advance care planning document.
Intervention (Visit 2):
In the intervention this first conversation (45-90 min) with a specifically trained ACP
facilitator aims to explain the goal and content of ACP and prompt the patient to reflect
upon his/her values and preferences for healthcare and discuss them with his/her caregiver.
In addition, the written decision aids will be explained and provided to the
patient/caregiver to be read at home. At the end of the meeting, the facilitator will ask to
set up the second meeting.
Intervention (Visit 3):
The second conversation of the ACP facilitator with the patient and her/his caregiver aims to
help the patient to specify her/his preferences and trans-late them into actionable
documentation. The discussions also aim to empower the caregiver to make sure that these
decisions are respected.
Post-intervention assessment (Visit 4):
The PI will start the meeting with a semi-structured interview (30-45 min) on the dyad's
subjective experience with the intervention, positive and nega-tive effects, and challenges
and suggestions to modify the intervention. Participants will also be asked to hand over
copies of ACP documents produced during the intervention or after it in order to be analysed.
After the interview, the PI will ask the patient and her/his relative to fill in psychometric
scales: Hospital anxiety and depression scale (HADS), Decisional conflict scale, Personal
autonomy scale and Zarit Burden Inventory.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |